CPC A61K 33/00 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/16 (2013.01); A61K 9/7023 (2013.01); A61K 31/045 (2013.01); A61K 31/133 (2013.01); A61K 31/198 (2013.01); A61K 31/4172 (2013.01); A61K 31/661 (2013.01); A61K 31/685 (2013.01); A61K 31/704 (2013.01); A61K 33/30 (2013.01); A61K 33/42 (2013.01); A61K 35/00 (2013.01); A61K 39/3955 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01)] | 20 Claims |
1. A method for treating rheumatoid arthritis or reducing a symptom of rheumatoid arthritis, the method comprising steps of:
(1) identifying a subject having rheumatoid arthritis or having a symptom thereof; and
(2) topically administering to the identified subject a transdermal formulation,
wherein the transdermal formulation comprises a penetrant or a penetration enhancer and an amount of one or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof, and
wherein the one or more buffering agents are selected from sodium bicarbonate, sodium carbonate, a carbonate salt, a bicarbonate salt, a phosphate buffer, TRIS, and lysine
wherein the amount of the one or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof is from about 10% to about 56% w/w relative to the formulation.
|